Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2018 - 2017 - 2016 - 2015

November 2017 Scleroderma News

The limited cutaneous form of systemic sclerosis (SSc) is associated with urinary incontinence (UI): an international multicentre study. Self–reported UI is frequent in SSc and disproportionally affects the limited cutaneous form of the disease and patients positive for Anticentromere Antibodies. PubMed, Rheumatology (Oxford), 08/01/2017. (Also see Interstitial Cystitis and Antibodies)

Inflammasome lights up in systemic sclerosis. The innate immune system and small RNA molecules known as microRNA are key factors in the development of scleroderma. BioMed Central, Arthritis Res Ther, 2017; 19: 205. (Also see Cytokines)

The Antiretroviral nelfinavir mesylate (NFV), a potential therapy for systemic scleroderma. NFV abrogates TGF–ß1–mediated myofibroblast differentiation and pulmonary fibrosis through off–target protein binding and supports consideration of this FDA–approved medication as an anti–fibrotic agent. PubMed, Arthritis Rheumatol, 09/21/2017. (Also see Treatments for Pulmonary Fibrosis and Fibroblasts)

Two years follow–up of an open–label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis (dcSSc). Rituximab appears to be safe and tolerable and it may have beneficial effects on skin involvement, on overall disease activity and on stabilization of internal organ status in early dcSSc. PubMed, Acta Clin Belg, 2017 Sep 11:1-7. (Also see Biologic Agents)

Selexipag for the treatment of connective tissue disease–associated pulmonary arterial hypertension (PAH). Selexipag delayed progression of PAH and was well–tolerated among PAH–Connective Tissue Disease patients, including those with PAH–Scleroderma and PAH–Systemic Lupus Erythematosus. PubMed, Eur Respir J, 2017 Aug 17;50(2). (Also see Uptravi® (Selexipag) for Pulmonary Hypertension)

Pandemic non–adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis (SSc). The non–adjuvanted influenza H1N1 virus vaccine proved to be safe and effective, independent of SSc clinical subtype, disease severity or therapy. PubMed, Rheumatology (Oxford), 09/08/2017. (Also see Vaccinations)

Capillary loss on nailfold capillary microscopy is associated with mortality in systemic sclerosis (SSc). The avascular score was associated with higher risk of death and may be a useful tool in prognostic evaluation of SSc. PubMed, Clin Rheumatol, 10/10/2017. (Also see Diagnosis of Scleroderma Pulmonary Involvement)

Hepatobiliary involvement (HBI) in systemic sclerosis (SSc) and the cutaneous subsets. Characteristics and survival of patients from the spanish rescle registry. Primary biliary cholangitis is the main cause of HBI and patients with SSc–HBI exhibited specific clinical and immunologic profile. Seminars in Arthritis and Rheumatism, 10/12/2017. (Also see Liver and Spleen Involvement)

IRF7 gene expression profile and methylation of its promoter region in patients with systemic sclerosis (SSc). Hypomethylation of the IRF7 promoter might play a role in SSc pathogenesis, probably through promoting the IRF7 expression in peripheral blood mononuclear cells of patients with SSc. PubMed, Int J Rheum Dis, 09/26/2017. (Also see Cytokines)

New Stem Cell Treatment for Diffuse Scleroderma Patients Available at Okyanos Center for Regenerative Medicine. A new treatment using adipose–derived regenerative cells (ADRCs) to treat hand problems caused by scleroderma is now available at Okyanos Center for Regenerative Medicine in Freeport, Grand Bahama. Scleroderma News, 10/12/2017. (Also see Stem Cell Transplantation)

Go to Scleroderma Medical News: October 2017

Many thanks to our recent donors, Jack and Elizabeth Lewis, Network for Good, Shirley Miller, Reata Pharmaceuticals, and United Way of Snohomish County! See ISN News for more donors. Click Here to Donate.


TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.

We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, report bad links, or update page content. Disclaimer. Privacy Policy.

The most important thing in the world to know about scleroderma is!